{"paper_id":"16a374e6-6cc3-4da9-8fb7-c233d80abaec","body_text":"Abstract\nThe endometrium is the unique inner lining of the uterus that responds to the cyclical ovarian hormones estrogen and progesterone with the ultimate aim of providing a suitable implantation environment for the developing embryo. Endometriosis is defined as the presence of endometrial-like tissue outside the uterus that induces a chronic, inflammatory reaction [1]. Endometriosis is a chronic and incurable disease that causes pain and is associated with infertility. Adenomyosis is an associated condition where the endometrial tissue exists within and grows into the uterine myometrium. Adenomyosis will not be specifically addressed in this chapter. The aim of this chapter is to empower the reader with the options of hormonal treatment in endometriosis. Insight into the mechanism of actions, efficacy, and side-effect profile will enable the reader to individualize treatment to the best benefit of the victims of endometriosis.\nAccess this chapter\nTax calculation will be finalised at checkout\nPurchases are for personal use only\nSimilar content being viewed by others\nReferences\nDunselman GA, Vermeulen N, Becker C, et al. European Society of Human Reproduction and Embryology (ESHRE). Guideline: Management of Women with endometriosis. Hum Reprod. 2014;29(3):400–12.\nMahmood TA, Templeton A. Prevalence and genesis of endometriosis. Hum Reprod. 1991;6(4):544–9.\nSampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927;14:422–69.\nMacer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. Obstet Gynecol Clin N Am. 2012;39(4):535–49.\nKoninckx PR, Ussia A, Adamyan L, et al. Pathogenesis of endometriosis: the genetic/epigenetic theory. Fertil Steril. 2019;111(2):327–40.\nHapangama D, Kamal A, Bulmer J. Estrogen receptor β: the guardian of the endometrium. Hum Reprod Update. 2015;21(2):174–93.\nPatel B, Elguero S, Thakore S, et al. Role of nuclear progesterone receptor isoforms in uterine pathophysiology. Hum Reprod Update. 2015 Mar;21(2):155–73.\nBulun SE, Monsivais D, Kakinuma T, et al. Molecular biology of endometriosis: from aromatase to genomic ab- normalities. Semin Reprod Med. 2015;33:220–4.\nAl-Sabbagh M, Lam EW, Brosens JJ. Mechanisms of endometrial progester-one resistance. Mol Cell Endocrinol. 2012;358:208–15.\nKarim A, Shafiee M, Aziz N, et al. Reviewing the role of progesterone therapy in endometriosis. Gynecol Endocrinol. 2018;35(1):1–7.\nMarjoribanks J, Ayeleke R, Farquhar C, et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015;30(7):CD001751.\nRafique S, DeCherney A. Medical management of endometriosis. Clin Obstet Gynecol. 2017;60(3):485–96.\nPrentice A, Deary A, Goldbeck-Wood S, et al. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2000;2:CD000346.\nHornstein M, Surrey E, Weisberg G, et al. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol. 1998;91(1):16–24.\nSurrey E, Taylor H, Giudice L, et al. Long-term outcomes of Elagolix in women with endometriosis: results from two extension studies. Obstet Gynecol. 2018 Jul;132(1):147–60.\nHarada T, Ohta I, Endo Y, et al. Selective estrogen receptor modulator for pain symptoms with endometriosis: an open-label clinical trial. Yonago Acta Med. 2017;60:227–33.\nSchindler A, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(Suppl 1):S7–S16.\nHayashi A, Tanabe A, Kawabe S, et al. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. J Ovarian Res. 2012;5:31.\nEbert A, Dong L, Merz M. Dienogest 2 mg daily in the treatment of adolescents with clinically suspected endometriosis: the Visanne study to assess safety in adolescents. J Pediatr Adolesc Gynecol. 2017;30:560–7.\nSchindler A. Dienogest in long-term treatment of endometriosis. Int J Women’s Health. 2011;3:175–84.\nCrosignani P, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2006;21(1):248–56.\nVercellini P, Vigano P, Somigliana E. The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis. Curr Opin Obstet Gynecol. 2005;17(4):359–65.\nWalch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis–a pilot study. Contraception. 2009;79(1):29–34.\nBulun S, Zeitoun K, Takayama K, et al. Molecular basis for treating endometriosis with aromatase inhibitors. Hum Reprod Update. 2000;6(5):413–8.\nShah D. Postmenopausal endometriosis: an enigma revisited. J Midlife Health. 2014 Oct;5(4):163–4.\nSampson J. Endometrial carcinoma of the ovary, arising in endometrial tissue in that organ. Arch Surg. 1925;10(1):1–72.\nDe Villiers T, Hall J, Pinkerton J, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric. 2016;19(4):313–5.\nBarrett-Connor E, Slone S, Greendale G, et al. The postmenopausal estrogen/progestin interventions study: primary outcomes in adherent women. Maturitas. 1997;27(3):261–74.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEditor information\nEditors and Affiliations\nRights and permissions\nCopyright information\n© 2021 International Society of Gynecological Endocrinology\nAbout this chapter\nCite this chapter\nde Villiers, T.J. (2021). Medical Management of Endometriosis, Present and Future with Special Reference to MHT in the Patient Previously Diagnosed with Endometriosis. In: Genazzani, A.R., Nisolle, M., Petraglia, F., Taylor, R.N. (eds) Endometriosis Pathogenesis, Clinical Impact and Management. ISGE Series. Springer, Cham. https://doi.org/10.1007/978-3-030-57866-4_14\nDownload citation\nDOI: https://doi.org/10.1007/978-3-030-57866-4_14\nPublished:\nPublisher Name: Springer, Cham\nPrint ISBN: 978-3-030-57865-7\nOnline ISBN: 978-3-030-57866-4\neBook Packages: MedicineMedicine (R0)","source_license":"CC0","license_restricted":false}